Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588721 | 1.00 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL2171729 | 1.00 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL5525241 | 0.87 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL6496296 | 0.87 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL5525240 | 0.87 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL9790466 | 0.84 | KDM1A (0.46) | KDM1AMTNR1AMTNR1B | |
| SCHEMBL9790462 | 0.84 | KDM1A (0.46) | KDM1AMTNR1AMTNR1B | |
| SCHEMBL9790470 | 0.84 | KDM1A (0.46) | KDM1AMTNR1AMTNR1B | |
| SCHEMBL30705332 | 0.83 | KDM1A (0.44) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9790505 | 0.82 | KDM1A (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139714-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-09-22 | — | — | US | claimed |
| US-8614267-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-24 | — | — | US | claimed |
| EP-2352735-B1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | claimed |
| EP-2346885-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | claimed |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | claimed |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | claimed |
| EP-2352735-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-2346885-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010051884-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | claimed |
| WO-2010051883-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | claimed |
| US-20250051299-A1 | PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12162854-B2 | Production method for fluoromethyl derivative | DAIKIN INDUSTRIES, LTD. (JP) | 2024-12-10 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240150269-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2024-05-09 | — | — | US | disclosed |
| CN-114787283-B | Composition for fiber-reinforced resin, and method for producing fiber-reinforced resin | 荒川化学工业株式会社 | 2024-02-27 | — | — | CN | disclosed |
| EP-1149067-B1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-1149067-A1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6310247-B1 | HAS APOPTOTIC ACTIVITY USEFUL FOR PROPHYLAXIS AND THERAPY OF CANCER | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2000035856-A1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-4219683-A | USING A PALLADIUM-THORIUM OXIDE CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | KDM1A 4102/4885MTNR1A 308/4885MTNR1B 101/4885 |
| US-20240150269-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | KDM1A 541/4885MTNR1A 2075/4885MTNR1B 2091/4885 |
| US-12162854-B2 | Production method for fluoromethyl derivative | AFF1, AFF2, ROS1 | KDM1A 888/4885MTNR1A 1558/4885MTNR1B 1009/4885 |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | HAO2, ALOX5, AOC3 | KDM1A 3686/4885MTNR1A 2196/4885MTNR1B 2052/4885 |
| US-20250051299-A1 | PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE | AFF1, AFF2, ROS1 | KDM1A 888/4885MTNR1A 1558/4885MTNR1B 1009/4885 |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | AOC3, SCO2, AOC2 | KDM1A 4128/4885MTNR1A 2985/4885MTNR1B 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.